Personalis (NASDAQ:PSNL) Reaches New 1-Year High – Here’s What Happened

Posted by Francis Steltz on Jul 1st, 2026

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $14.18 and last traded at $13.90, with a volume of 461910 shares trading hands. The stock had previously closed at $13.40.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PSNL. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, Morgan Stanley cut their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

View Our Latest Stock Report on Personalis

Personalis Stock Performance

The firm has a market capitalization of $1.45 billion, a P/E ratio of -13.56 and a beta of 2.28. The firm’s 50-day moving average is $8.69 and its 200 day moving average is $8.34.

Personalis (NASDAQ:PSNL – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. As a group, research analysts expect that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. The trade was a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. This trade represents a 20.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 335,032 shares of company stock valued at $4,091,929. 4.20% of the stock is owned by corporate insiders.

Institutional Trading of Personalis

Institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its position in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. Legal & General Group Plc bought a new stake in Personalis during the 2nd quarter worth about $30,000. International Assets Investment Management LLC acquired a new position in shares of Personalis during the 4th quarter worth about $31,000. BNP Paribas Financial Markets boosted its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Personalis in the 1st quarter valued at about $47,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.